Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Prevention of Acute GvHD
NCT00201799Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Feb 2004
- Primary completion
- Aug 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab in graft-versus-host disease (GVHD), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Feb 2004; status: completed.
02
Drugs
infliximab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00201799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201799.